Annexin-A1 targeted therapy beats several cancers

A new study published in Nature's cancer journal Oncogene highlights the effectiveness of MDX-124, the first therapeutic drug to target annexin-A1, a protein which is overexpressed in several cancer types and promotes tumour progression.

Related Keywords

Sussex ,East Sussex ,United Kingdom ,Chris Parris ,Fiona Dempsey ,Dr Hussein Al Ali At Anglia Ruskin University ,Anglia Ruskin University ,Sussex Medical School ,Professor Chris Parris ,Professor Chris Pepper ,Life Sciences ,Scientific Operations ,Cancer ,Fell ,Ntibody ,N Vitro ,N Vivo ,Medical School ,Monoclonal Antibody ,Oncogene ,Protein ,Research ,